Skip to main content
SpringerLink
Log in

Recommended Treatment Modalities for Hyperandrogenism

  • Chapter
Book cover Polycystic Ovary Syndrome

Part of the book series: Contemporary Endocrinology ((COE))

  • 1315 Accesses

Summary

Improvement in androgenic symptoms generally requires ovarian androgen suppression. Insulin sensitizers may also be effective. Androgen suppression (e.g., oral contraceptives or metformin) alone produces modest decreases in the degree of hirsutism; concomitant antiandrogen therapy improves effectiveness considerably. The use of androgen receptor (AR) competitive inhibitors such as spironolactone, flutamide, or cyproterone acetate is recommended for the treatment of dermatologic hyperandrogenic symptoms, principally hirsutism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.

    Google Scholar 

  2. Rosenfield RL. Hirsutism. N Engl J Med 2005;353:2578–88.

    Article  PubMed  CAS  Google Scholar 

  3. Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic ovary syndrome and risk for myocardial infarction evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599–604.

    Article  PubMed  CAS  Google Scholar 

  4. Santoro N, Torrens J, Crawford S, Allsworth JE, Finkelstein JS, Gold EB, Korenman S, Lasley WL, Luborsky JL, McConnell D, Sowers MF, Weiss G. Correlates of circulating androgens in mid-life women: the Study of Women’s Health Across the Nation (SWAN). J Clin Endocrinol Metab 2005;90:4836–45.

    Article  PubMed  CAS  Google Scholar 

  5. Pascal MM, Pugeat M, Robert M, Rousset H, Déchaud H, Dutrieux-Berger N, Tourniaire J. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol 1994;41: 571–6.

    Google Scholar 

  6. Azziz R, Dewailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994;78:810–5.

    Article  PubMed  CAS  Google Scholar 

  7. Cousin P, Calemard-Michel L, Lejeune H, Grenot C, Baret C, Brébant C, Pugeat M Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab 2004;89:917–24.

    Article  PubMed  CAS  Google Scholar 

  8. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005;352:1223–36.

    Article  PubMed  CAS  Google Scholar 

  9. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29–38.

    Article  PubMed  CAS  Google Scholar 

  10. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817–23.

    Article  PubMed  CAS  Google Scholar 

  11. Diamanti-Kandarakis E, Baillargeon, J-P, Iuorno MJ, Jakubowicz DJ, Nestler JE. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927–32.

    Article  PubMed  CAS  Google Scholar 

  12. Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creastas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil Steril 2006;85:420–7.

    Article  PubMed  CAS  Google Scholar 

  13. Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spironolactones: mechanism of action. Endocrinology 1975;97:52–8.

    PubMed  CAS  Google Scholar 

  14. Farquhar C, Lee O, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 2003;4:CD000194.

    PubMed  Google Scholar 

  15. Christy NA, Franks AS, Cross LB. Spironolactone for hirsutism in polycystic ovary syndrome. Ann Pharmacother 2005;39:1517–21.

    Article  PubMed  CAS  Google Scholar 

  16. Shaw JC, White LE. Long-term safety of spironolactone in acne: results of an 8-year follow up study. J Cut Med Surg 2002;6:541–5.

    Article  Google Scholar 

  17. Vincens M, Mercier-Bodard Ch, Mowszowicz I, Kuttenn F, Mauvais-Jarvis P. Testosterone-estradiol binding globulin (TeBG) under cyproterone acetate (CPA) and percutaneous estradiol treatment of hirsutism. Gynecologicl Endocrinology 1988;208, suppl. 2:Abst 260.

    Google Scholar 

  18. Vander Spuy ZM, Le Roux PA. Cyproterone acetate for hirsutism. Cochrane Database System Rev 2003;4 CD001125.

    Google Scholar 

  19. O’Brien RC, Cooper ME, Lamurray RML, Seeman E, Thomas AK, Jerums G. Comparison of sequential cyproterone acetate/estrogen vs. spironolactone/oral contraceptive in the treatment of hirsutism. J Endocrinol Metab 1991;72:1008–13.

    Article  CAS  Google Scholar 

  20. Krotkiewski M, Landin K, Dahlgren E, Janson PO, Holm G. Effect of two modes of antiandrogen treatment on insulin sensitivity and serum leptin in women with PCOS. Gynecol Obstet Invest 2003;55:88–95.

    Article  PubMed  CAS  Google Scholar 

  21. Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1998;13:2706–11.

    PubMed  CAS  Google Scholar 

  22. Rittmaster RS. Hirsutism. Lancet 1997;349:191–5.

    Article  PubMed  CAS  Google Scholar 

  23. Muderris II, Bayram F, Sahin Y, Kelestimur F. A comparison between two doses of flutamide (250 mg/d and 500 mg/d) in the treatment of hirsutism. Fertil Steril 1997;68:644–7.

    Google Scholar 

  24. Couzinet B, Pholsena M, Young J, Schaison G. 1993 The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin Endocrinol (Oxf) 39:157–62.

    CAS  Google Scholar 

  25. De Leo V, Lanzetta D, D’Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99–102.

    Google Scholar 

  26. Cusan L, Dupont A, Belanger A, Tremblay RR, Manhes G, Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990;23:462–9.

    Article  PubMed  CAS  Google Scholar 

  27. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. 1994 Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 61:281–7.

    PubMed  CAS  Google Scholar 

  28. Dodin S, Faure N, Cedrin I, Mechain C, Turcot-Lemay L, Guy J, Lemay A. Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin Endocrinol (Oxf) 1995;43:575–82.

    CAS  Google Scholar 

  29. Venturoli S, Paradisi R, Bagnoli A, Colombo FM, Ravaioli B, Vianello F, Mancini F, Gualerzi B, Porcu E, Seracchioli R. Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism. Horm Res 2001;56:5–31.

    Article  Google Scholar 

  30. Andrade RJ, Lucena MI, Fernandez MC, Suarez F, Montero JL, Fraga E, Hidalgo F. Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet 1999;353:983.

    Article  PubMed  CAS  Google Scholar 

  31. Grigoriou O, Papadias C, Konidaris S, Antoniou G, Karakitsos P, Giannikos L. Comparison of flutamide and cyproterone acetate in the treatment of hirsutism: a randomized controlled trial. Gynecol Endocrinol 1996;10:119–23.

    Article  PubMed  CAS  Google Scholar 

  32. Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravailoli B. Bagnoli A, Paradisi R, Flamigni C. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate – estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304–10.

    Article  PubMed  CAS  Google Scholar 

  33. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo controlled trial. J Clin Endocrinol Metab 2000;85:89–94.

    Article  PubMed  CAS  Google Scholar 

  34. Inal MM, Yildirim Y, Taner CE. Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study. Fertil Steril 2005;841693–7.

    Google Scholar 

  35. Beigi A, Sobhi A, Zarrinkoub F. Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism. Int J Gynaecol Obstet 2004; 87:29–33.

    Article  PubMed  CAS  Google Scholar 

  36. Kelestimur F, Everest H, Unluhizarci K, Bayram F, Sahin Y. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism. Eur J Endocrinol 2004;150(3):351–4.

    Article  PubMed  CAS  Google Scholar 

  37. Harborne L, Fleming R, Lyall H, Norman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003;361:1894–901.

    Article  PubMed  CAS  Google Scholar 

  38. Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4116–23.

    Article  PubMed  CAS  Google Scholar 

  39. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2699–705.

    Article  PubMed  CAS  Google Scholar 

  40. Ibanez L, De Zegher F. Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 2003;88:4720–4.

    Article  PubMed  CAS  Google Scholar 

  41. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Michel Pugeat MD PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nisrin Kaddar PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Véronique Raverot PHD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University, Chicago, IL

    Andrea Dunaif MD

  2. Department of Reproductive Medicine, University of California, San Diego School of Medicine, La Jolla, CA

    R. Jeffrey Chang MD

  3. Institute of Reproductive and Developmental Biology, Imperial College London, London, UK

    Stephen Franks MD, FMEDSCI

  4. Department of Ob/Gyn, Penn State College of Medicine, Hershey, PA

    Richard S. Legro MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press

About this chapter

Cite this chapter

Pugeat, M., Kaddar, N., Raverot, V. (2008). Recommended Treatment Modalities for Hyperandrogenism. In: Dunaif, A., Chang, R.J., Franks, S., Legro, R.S. (eds) Polycystic Ovary Syndrome. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59745-108-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-108-6_18

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-831-7

  • Online ISBN: 978-1-59745-108-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation